Century TherapeuticsIPSC
About: Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Employees: 165
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
400% more call options, than puts
Call options by funds: $10K | Put options by funds: $2K
200% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
7% more funds holding
Funds holding: 67 [Q3] → 72 (+5) [Q4]
3.99% less ownership
Funds ownership: 46.8% [Q3] → 42.81% (-3.99%) [Q4]
46% less capital invested
Capital invested by funds: $67.8M [Q3] → $36.8M (-$31M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 57 / 186 met price target | 268%upside $2 | Buy Maintained | 3 Apr 2025 |
Chardan Capital Geulah Livshits 7% 1-year accuracy 4 / 60 met price target | 1,187%upside $7 | Buy Maintained | 24 Mar 2025 |
Piper Sandler Edward Tenthoff 15% 1-year accuracy 5 / 33 met price target | 268%upside $2 | Overweight Maintained | 20 Mar 2025 |
Financial journalist opinion
